As the Australian market navigates a week marked by geopolitical tensions and mixed economic data, investor sentiment remains cautious. Despite this hesitancy, there is still interest in exploring opportunities within the realm of penny stocks, which often represent smaller or newer companies with potential for growth. While the term "penny stocks" may seem outdated, these investments can offer a unique blend of affordability and potential when supported by strong financials.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.46 A$131.83M ★★★★★☆ Dusk Group (ASX:DSK) A$0.90 A$56.04M ★★★★★★ IVE Group (ASX:IGL) A$3.03 A$467.04M ★★★★★☆ MotorCycle Holdings (ASX:MTO) A$2.93 A$216.42M ★★★★★★ Veris (ASX:VRS) A$0.072 A$38.91M ★★★★★★ West African Resources (ASX:WAF) A$3.72 A$4.25B ★★★★★★ SKS Technologies Group (ASX:SKS) A$3.78 A$435.91M ★★★★★★ Service Stream (ASX:SSM) A$2.26 A$1.38B ★★★★★★ EDU Holdings (ASX:EDU) A$0.70 A$100.75M ★★★★★☆ MaxiPARTS (ASX:MXI) A$2.19 A$121.64M ★★★★★★

Click here to see the full list of 412 stocks from our ASX Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

IVE Group

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: IVE Group Limited, along with its subsidiaries, operates in the marketing sector in Australia and has a market capitalization of A$467.04 million.

Operations: The company's revenue is primarily derived from its advertising segment, which generated A$959.25 million.

Market Cap: A$467.04M

IVE Group Limited, with a market capitalization of A$467.04 million, has demonstrated solid financial performance in the marketing sector. Its revenue from advertising stands at A$959.25 million, indicating significant business activity. The company's debt is well-covered by operating cash flow and interest payments are comfortably managed by EBIT. IVE's earnings grew 69.2% last year, outpacing the media industry significantly and reflecting high-quality past earnings with an improved net profit margin of 4.9%. While its net debt to equity ratio remains high at 51.7%, the company offers good relative value compared to peers and industry standards.

Dive into the specifics of IVE Group here with our thorough balance sheet health report. Assess IVE Group's future earnings estimates with our detailed growth reports.ASX:IGL Debt to Equity History and Analysis as at Jan 2026

Judo Capital Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Judo Capital Holdings Limited, with a market cap of A$2.10 billion, provides a range of banking products and services specifically tailored for small and medium businesses in Australia through its subsidiaries.



Operations: The company generates revenue primarily from its Small and Medium Enterprises (SMEs) Lending segment, amounting to A$347.4 million.

Market Cap: A$2.1B

Judo Capital Holdings Limited, with a market cap of A$2.10 billion, focuses on SME lending in Australia and has shown robust financial metrics. The company reported revenue of A$347.4 million from its SME Lending segment, reflecting substantial business operations. Despite earnings growth decelerating to 23.6% last year from a five-year average of 50.5%, Judo remains profitable and has high-quality earnings with improved profit margins at 24.9%. The Loans to Deposits ratio is appropriate at 125%, though the bad loans ratio is elevated at 3.4%. Trading below estimated fair value by 25%, Judo presents potential investment interest within the penny stock category in Australia.

Take a closer look at Judo Capital Holdings' potential here in our financial health report. Gain insights into Judo Capital Holdings' outlook and expected performance with our report on the company's earnings estimates.ASX:JDO Debt to Equity History and Analysis as at Jan 2026

Mesoblast

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Mesoblast Limited, with a market cap of A$3.46 billion, is involved in developing regenerative medicine products across Australia, the United States, Singapore, and Switzerland.

Operations: The company generates revenue primarily from the development of its cell technology platform for commercialization, amounting to $17.20 million.

Market Cap: A$3.46B

Mesoblast Limited, with a market cap of A$3.46 billion, is actively engaged in developing regenerative medicine products and has recently made significant strides with its cell therapy product rexlemestrocel-L for chronic low back pain (CLBP). Despite being unprofitable, the company has reduced losses over five years and maintains a strong cash position exceeding its liabilities. The FDA's positive feedback on Mesoblast's Phase 3 trial results for pain reduction and opioid cessation highlights potential efficacy in addressing the U.S. opioid crisis. Management changes reflect strategic shifts towards commercialization as Mesoblast seeks to expand its revenue-generating capabilities.

Click here to discover the nuances of Mesoblast with our detailed analytical financial health report. Review our growth performance report to gain insights into Mesoblast's future.ASX:MSB Financial Position Analysis as at Jan 2026

Summing It All Up

Take a closer look at our  ASX Penny Stocks list of 412 companies by clicking here. Curious About Other Options? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:IGL ASX:JDO and ASX:MSB.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]